Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JP Morgan Upgrades C4 Therapeutics to Neutral, Announces $6 Price Target

Author: Benzinga Newsdesk | January 29, 2024 06:45am
JP Morgan analyst Eric Joseph upgrades C4 Therapeutics (NASDAQ:CCCC) from Underweight to Neutral and announces $6 price target.

Posted In: CCCC

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist